Are SDAMs effective in the treatment of major depressive disorder (clinical depression)?

Updated: Aug 06, 2020
  • Author: Jerry L Halverson, MD; Chief Editor: David Bienenfeld, MD  more...
  • Print

In clinical trials, brexpiprazole was added to existing antidepressant therapy in patients who had failed multiple trials of antidepressant therapy. Patients enrolled met DSM-IV-TR criteria for MDD. Brexpiprazole (2 mg and 3 mg daily) plus antidepressant therapy was superior to placebo plus antidepressant therapy on the primary endpoint (ie, change in Montgomery-Åsberg Depression Rating Scale scores). [115]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!